Adam S. Grossman, the President and CEO of ADMA Biologics, Inc., has disclosed multiple stock transactions in a recent SEC filing. This update is significant as it highlights Grossman's ongoing investment in the company, which may impact investor confidence and market perception.

ADMA Biologics, based in Ramsey, New Jersey, is involved in the biological products sector, specifically focusing on products that do not include diagnostic substances. The company is publicly traded under the ticker symbol ADMA and has been active in the market with various filings, including recent Form 4 and Form 144 submissions.

According to the latest filing, Grossman executed several transactions on November 5, 2026. He acquired 105,000 shares of common stock at a price of $5.40 per share. Additionally, he sold 105,000 shares at $12.00 each and another 42,000 shares at the same price. Following these transactions, Grossman retains ownership of 2,072,777 shares of common stock.

The filing indicates that these transactions were conducted under a Rule 10b5-1 trading plan, which allows executives to set up a predetermined schedule for buying and selling stock. This plan is designed to prevent accusations of insider trading by establishing a clear timeline for transactions.

Grossman's actions may affect various stakeholders, including investors, employees, and analysts monitoring ADMA Biologics. His significant stock holdings and transactions could signal confidence in the company’s future performance, potentially influencing investor sentiment and market dynamics.

Looking ahead, the filing does not specify any upcoming events or additional filings related to these transactions. However, given the nature of the biological products industry, ongoing developments and regulatory changes could impact ADMA Biologics and its market position.